The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide‐based therapy
暂无分享,去创建一个
G. Morgan | W. Gregory | W. Tapper | D. Gonzalez | S. Hockley | B. Walker | F. Ross | F. Davies | G. Jackson | C. Wardell | Z. Konn | L. Chiecchio | K. Boyd | G. Dagrada | J. Anthony Child | B. Walker
[1] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Morgan,et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.
[3] T. Soussi,et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma , 2010, Haematologica.
[4] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Hose,et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation , 2010, Haematologica.
[6] P. Sonneveld,et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. , 2010, Blood.
[7] P. Moreau,et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Cross,et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context , 2009, Haematologica.
[9] B. Barlogie,et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 , 2009, British journal of haematology.
[10] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[11] D. Horsman,et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. , 2009, Blood.
[12] H. Einsele,et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). , 2009, Blood.
[13] F. Zhan,et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. , 2008, Blood.
[14] B. Barlogie,et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. , 2008, Blood.
[15] G. Morgan,et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. , 2007, Blood.
[16] T Hamblin,et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.
[17] J. Bourdon,et al. p53 and its isoforms in cancer , 2007, British Journal of Cancer.
[18] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[19] R. Fonseca,et al. Clinical significance of TP53 mutation in myeloma , 2007, Leukemia.
[20] Cheng Li,et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.
[21] G. Morgan,et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma , 2006, Leukemia.
[22] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[23] D. Reece,et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. , 2004, Blood.
[24] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[25] M. Fiegl,et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. , 1998, Blood.
[26] S. Davis,et al. p53 gene mutations in multiple myeloma. , 1997, Molecular pathology : MP.